The Daily Pulse

Technology

Medical device maker Science Corporation reaches $3.5 billion valuation following new investment round

Reported by Kavya Rao (Senior Writer) · TechCrunch ·

Source: TechCrunch
Worth knowing
Medical device maker Science Corporation reaches $3.5 billion valuation following new investment roundPhoto: Wikimedia Commons

Science Corporation secured a massive $400 million Series D funding round to expand its work on vision restoration. The fresh capital pushes the medical tech firm to a $3.5 billion valuation, according to sources familiar with the transaction. Max Hodak, an ex-president of Neuralink, launched the startup in 2021 to build advanced tools that link with human neural pathways.

Funding And Backers

A group of prominent financial backers and institutions contributed to the latest financing. The roster of investors features Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.

Products And Trials

The company's flagship device, named PRIMA, is a hybrid chip and wearable system designed to restore sight for patients suffering from age-related macular degeneration. Regulators in Europe have already greenlit the technology, and it is currently on the market in Germany. Leadership revealed plans to expand testing to individuals affected by Stargardt's disease, another condition that leads to vision loss.

US Approval Strategy

Executives plan to use the new money to introduce the technology to the United States market. The firm is pursuing approval through a special regulatory pathway meant for rare illnesses, having convinced federal officials that severe vision loss in both eyes qualifies under the guidelines. Meanwhile, the enterprise continues working on its long-term goal of building bio-hybrid sensors using both silicon and live neurons. Collaborating with Yale neurosurgeon Murat Günel, the team is planning initial human tests for conditions like Parkinson's disease.

Context

Medical startups often rely on venture capital funding rounds to finance expensive clinical trials and regulatory approvals over many years. Devices that interface with the human nervous system require rigorous safety testing before they can be sold to patients or used widely in hospitals.

ExplainerWhy this matters

What Happened

Science Corporation secured a major injection of venture capital to fund the commercial expansion and regulatory clearance of its neural technology products.

Why It Matters

Brain-computer interfaces and neural implants represent a major frontier in modern medicine, offering potential pathways to treat blindness, neurological disorders, and severe injuries that currently have limited treatment options. Bringing these devices through regulatory approval in major markets like the United States is a critical hurdle for turning experimental laboratory science into widely available clinical care.

What Happens Next

The company will advance its regulatory filings in the United States while pursuing clinical trials for new medical conditions. Observers will watch for updates on upcoming human trials for Parkinson's disease and broader patient access to the PRIMA vision system.

Read more at TechCrunch →